Large Negative Electronic Compressibility of LaAlO3-SrTiO3 Interfaces with Ultrathin LaAlO3 Layers

A two-dimensional electron liquid is formed at the n-type interface between SrTiO3 and LaAlO3. Here we report on Kelvin probe microscopy measurements of the electronic compressibility of this electron system. The electronic compressibility is found to be negative for carrier densities of \approx10^13/cm^2. At even smaller densities, a metal-to-insulator transition occurs. These local measurements corroborate earlier measurements of the electronic compressibility of LaAlO3-SrTiO3 interfaces obtained by measuring the capacitance of macroscopic metal-LaAlO3-SrTiO3 capacitors

Diodes with Breakdown Voltages Enhanced by the Metal-Insulator Transition of LaAlO3_3-SrTiO3_3 Interfaces

Using the metal-insulator transition that takes place as a function of carrier density at the LaAlO$_3$-SrTiO$_3$ interface, oxide diodes have been fabricated with room-temperature breakdown voltages of up to 200 V. With applied voltage, the capacitance of the diodes changes by a factor of 150. The diodes are robust and operate at temperatures up to 270 C

Two-dimensional electron liquid state at LaAlO3-SrTiO3 interfaces

Using tunneling spectroscopy we have measured the spectral density of states of the mobile, two-dimensional electron system generated at the LaAlO3-SrTiO3 interface. As shown by the density of states the interface electron system differs qualitatively, first, from the electron systems of the materials defining the interface and, second, from the two-dimensional electron gases formed at interfaces between conventional semiconductors

Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: A Single-Center, Phase I, Randomized, Four-Way Crossover Study

The aim of this study was to evaluate the effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers. Healthy volunteers were randomized to one of four treatment sequences (n=112) involving four successive treatments in different order: pasireotide 600 mu g (therapeutic dose) or 1,950 mu g (maximum tolerated dose) bid by subcutaneous injection (sc), placebo injection and oral moxifloxacin. Maximum QTcI occurred 2 hours post-dose for both doses of pasireotide. Mean QTcI was 13.2milliseconds (90% CI: 11.4, 15.0) and 16.1milliseconds (90% CI: 14.3, 17.9) for the 600 and 1,950 mu g bid doses, respectively. Maximal placebo-subtracted change in QTcI from baseline for moxifloxacin was 11.1 (90% CI: 9.3, 12.9) milliseconds. Both pasireotide doses caused a reduction in heart rate: maximal heart rate change compared with placebo occurred at 1hour for pasireotide 600 mu g bid and at 0.5hours for pasireotide 1,950 mu g bid, with heart rate reductions of 10.4 and 14.9bpm, respectively. At the therapeutic dose of 600 mu g, pasireotide has a modest QT-prolonging effect. The relatively small increase of approximate to 3milliseconds in QTcI in the presence of a 3.25-fold increase in dose suggests a relatively flat dose-effect relationship of pasireotide on QTcI in healthy volunteers. No safety concerns for pasireotide were identified during the stud